Autolus Therapeutics plc - American Depositary Share (AUTL) News
Filter AUTL News Items
AUTL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AUTL News Highlights
- AUTL's 30 day story count now stands at 3.
- Over the past 12 days, the trend for AUTL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and OBE are the most mentioned tickers in articles about AUTL.
Latest AUTL News From Around the Web
Below are the latest news stories about AUTOLUS THERAPEUTICS PLC that investors may wish to consider to help them evaluate AUTL as an investment opportunity.
Autolus Therapeutics Announces Changes to its Board of Directors- Appointment of Elisabeth (“Lis”) Leiderman, M.D. - Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Elisabeth Leiderman, M.D. to the Board of Directors. Additionally, the Company announced that Kapil Dhingra M.D., who has served on Autolus’ Board of Directors since May 2015, has advised the Boa |
12 Most Promising Cancer Stocks According to AnalystsIn this piece, we will take a look at the 12 most promising cancer stocks according to analysts. If you want to skip our overview of the latest trends in the cancer treatment sector, then you can take a look at the 5 Most Promising Cancer Stocks According to Analysts. The advent of technology and […] |
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic burden at lymphodepletionLonger-term data from a pooled analysis from the ALLCAR19 study and FELIX Phase Ib in r/r B-ALL showed durable remissions with obe-cel as a stand-alone therapy in a subset of patients after a median follow up of >3 yearsAdditionally, ALLCAR19 extension cohorts demonstrated |
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL)Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has |
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMTReview of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 extension with obe-cel, as well as initial data from the AUTO8 MCARTY Phase I Study LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host an i |
Autolus Therapeutics announces participation in upcoming conferencesLONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November. Truist Securities BioPharma Symposium Panel: Considerations for an Oncology Company’s Autoimmune Side HustleDate and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, |
Investors in Autolus Therapeutics (NASDAQ:AUTL) from five years ago are still down 88%, even after 50% gain this past weekOver the last month the Autolus Therapeutics plc ( NASDAQ:AUTL ) has been much stronger than before, rebounding by 83... |
Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2023 Earnings Call TranscriptAutolus Therapeutics plc (NASDAQ:AUTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Third Quarter 2023 Financial Results Conference Call and Business Update. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please […] |
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentationsobe-cel: oral presentation – pooled analysis of the ongoing FELIX Phase Ib/II study AUTO8: oral presentation of MCARTY Phase I Study obe-cel: poster presentation - pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 extension obe-cel: poster presentation - CMC demonstrating the robustness of obe-cel manufacturing LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T c |
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesObe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 Updated clinical data at the American Society of Hematology (ASH) meeting in December 2023: Long-term follow-up and sub-group analysis from the FELIX trial of obe-cel and initial data from a study of AUTO8 in multiple myelomaContinued progress with co |